Accuray Incorporated

NMS: ARAY
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Accuray Incorporated's price action across multiple timeframes using regression channels and statistical scoring.

Get ARAY Z-Score →

About Accuray Incorporated

Healthcare Medical Devices
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

📊 Fundamental Analysis

Accuray Incorporated demonstrates a profit margin of -8.2%, which is below the sector average, suggesting competitive pressure.

The company recently reported -12.0% revenue growth, which is negative, indicating a recent decline in revenue.

Return on Equity (ROE) is -70.3%, which indicates that capital utilization is currently under pressure.

At a current price of $0.39, ARAY currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.33 - $2.10).

🏥 Financial Health

🔴 Profit Margin Weak
🔴 Debt/Equity Elevated
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
🔴 Beta (Risk) High Volatility

Key Financials

Market Cap
$46.31M
Trailing P/E
--
Forward P/E
-13.00
Beta (5Y)
1.32
52W High
$2.10
52W Low
$0.33
Avg Volume
1.22M
Day High
Day Low
Get ARAY Z-Score on Dashboard 🚀